A clinical review of bleomycin--a new antineoplastic agent.

PubWeight™: 2.53‹?› | Rank: Top 2%

🔗 View Article (PMID 4122362)

Published in Cancer on April 01, 1973


R H Blum, S K Carter, K Agre

Articles citing this

Thermochemotherapy: synergism between hyperthermia (42-43 degrees) and adriamycin (of bleomycin) in mammalian cell inactivation. Proc Natl Acad Sci U S A (1975) 1.75

Intralesional bleomycin injection (IBI) treatment for haemangiomas and congenital vascular malformations. Pediatr Surg Int (2004) 1.70

Studies with bleomycin and misonidazole on aerated and hypoxic cells. Br J Cancer (1978) 1.61

The skin biopsy in the diagnosis of acute graft-versus-host disease in man. Am J Pathol (1977) 1.58

Morphometric estimates of infiltrative cellular changes during the development of bleomycin-induced pulmonary fibrosis in hamsters. Am J Pathol (1983) 1.50

IL-17 producing gammadelta T cells are required for a controlled inflammatory response after bleomycin-induced lung injury. Inflammation (2008) 1.49

Lack of metabolism as the biochemical basis of bleomycin-induced pulmonary toxicity. Proc Natl Acad Sci U S A (1983) 1.29

Bleomycin-induced diffuse interstitial pulmonary fibrosis in baboons. J Clin Invest (1978) 1.13

Comparison of the sequence specificity of bleomycin cleavage in two slightly different DNA sequences. Nucleic Acids Res (1985) 1.12

Factors influencing postoperative morbidity and mortality in patients treated with bleomycin. Br Med J (1978) 1.04

Prevention of bleomycin-induced pulmonary fibrosis after adenovirus-mediated transfer of the bacterial bleomycin resistance gene. J Clin Invest (1997) 1.02

Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: a review of patients with germ cell tumours. Br J Cancer (1998) 0.95

Bleomycin lung: a case report. BMJ Case Rep (2009) 0.92

Development of acute lung injury after the combination of intravenous bleomycin and exposure to hyperoxia in rats. Thorax (1987) 0.89

Sequence-selective binding of phleomycin to DNA. Biochem J (1987) 0.89

Catalytic mechanism of bleomycin N-acetyltransferase proposed on the basis of its crystal structure. J Biol Chem (2009) 0.85

Pulmonary veno-occlusive disease after chemotherapy. Thorax (1985) 0.85

The role of the receptor for advanced glycation end-products in a murine model of silicosis. PLoS One (2010) 0.85

Diethylpyrocarbonate and permanganate provide evidence for an unusual DNA conformation induced by binding of the antitumour antibiotics bleomycin and phleomycin. Nucleic Acids Res (1988) 0.84

Interstitial lung disease in a patient treated with 5-fluorouracil and mitomycin C. Br Med J (1978) 0.84

Effects of a calmodulin inhibitor on bleomycin-induced lung inflammation in hamsters. Biochemical, morphometric, and bronchoalveolar lavage data. Am J Pathol (1986) 0.84

Bleomycin-induced lung injury in the rat: effects of the platelet-activating factor (PAF) receptor antagonist BN 52021 and platelet depletion. Environ Health Perspect (1990) 0.83

Interaction of bleomycin with a bent DNA fragment. Biochem J (1992) 0.82

A fatal hyperpyrexial response to bleomycin following prior therapy: a case report and literature review. Yale J Biol Med (1983) 0.81

Anatomy of Clara cell secretion: surface changes observed by scanning electron microscopy. J Anat (1993) 0.81

Postoperative acute respiratory distress syndrome in patients with previous exposure to bleomycin. Mayo Clin Proc (2014) 0.81

Common emergencies in cancer medicine: infectious and treatment-related syndromes, Part II. J Natl Med Assoc (1994) 0.80

The synergistic effect of bleomycin, triamcinolone and epinephrine in treatment of hemangioma and arteriovenous malformations. World J Plast Surg (2012) 0.80

Progress report. Cytotoxic therapy for gastrointestinal carcinoma. Gut (1976) 0.79

Eosinophilic pneumonia associated with bleomycin in a patient with mediastinal seminoma: a case report. J Med Case Rep (2010) 0.78

Bleomycin induced urethral stricture in Hodgkin's disease. Indian J Urol (2009) 0.78

Hyperpigmentation after bleomycin therapy. Ultrastructural study. Arch Dermatol Res (1978) 0.77

The DNA sequence specificity of bleomycin cleavage in telomeric sequences in human cells. J Biol Inorg Chem (2012) 0.77

The effect of bleomycin and its combined effect with radiation on murine squamous carcinoma treated in vivo. Br J Cancer (1974) 0.76

Bleomycin-induced flagellate dermatitis. BMJ Case Rep (2013) 0.75

Structural biological study of self-resistance determinants in antibiotic-producing actinomycetes. J Antibiot (Tokyo) (2015) 0.75

Chemotherapy for non-seminomatous germ-cell tumours. J R Soc Med (1985) 0.75

Pulmonary toxicity of antineoplastic agents. West J Med (1977) 0.75

An A,B,C,D of cancer chemotherapy. West J Med (1979) 0.75

Role of non-transferrin bound iron in iron overload and liver dysfunction in long term survivors of acute leukaemia and bone marrow transplantation. J Clin Pathol (1996) 0.75

Progress of bleomycin-induced lung fibrosis in rabbits. Br J Exp Pathol (1986) 0.75

Drug eruptions. Postgrad Med J (1985) 0.75

Fulminant hyperpyrexia induced by bleomycin. Postgrad Med J (1989) 0.75

Endoscopic local injection of a new drug delivery formulation, anticancer drug bound to carbon particles, for digestive cancers: pilot study. J Gastroenterol (1997) 0.75

1H, 13C, and 15N assignment of a bleomycin resistance protein in its native form and in a complex with Zn2+ ligated bleomycin. J Biomol NMR (2000) 0.75

Glycosides Based Standardized Fenugreek Seed Extract Ameliorates Bleomycin-induced Liver Fibrosis in Rats Via Modulation of Endogenous Enzymes. J Pharm Bioallied Sci (2017) 0.75

Articles by these authors

Interferon alfa-2b adjuvant therapy of high-risk resected cutaneous melanoma: the Eastern Cooperative Oncology Group Trial EST 1684. J Clin Oncol (1996) 9.68

Pain and its treatment in outpatients with metastatic cancer. N Engl J Med (1994) 9.54

High- and low-dose interferon alfa-2b in high-risk melanoma: first analysis of intergroup trial E1690/S9111/C9190. J Clin Oncol (2000) 4.60

Adriamycin. A new anticancer drug with significant clinical activity. Ann Intern Med (1974) 2.77

Randomized comparison of doxorubicin alone versus ifosfamide plus doxorubicin or mitomycin, doxorubicin, and cisplatin against advanced soft tissue sarcomas. J Clin Oncol (1993) 2.28

The integration of chemotherapy into a combined modality approach for cancer treatment. VI. Pancreatic adenocarcinoma. Cancer Treat Rev (1975) 2.10

Pancreatic islet cell carcinoma. II. Results of therapy with streptozotocin in 52 patients. Ann Intern Med (1973) 2.01

Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol (1998) 1.94

Pancreatic islet cell carcinoma. I. Clinical features of 52 patients. Ann Intern Med (1973) 1.87

Adriamycin-a review. J Natl Cancer Inst (1975) 1.68

The chemotherapy of urologic cancer. Cancer (1975) 1.32

Integration of chemotherapy into combined modality treatment of solid tumors VII. Adenocarcinoma of the breast. Cancer Treat Rev (1976) 1.31

Carboplatin: the clinical spectrum to date. Cancer Treat Rev (1985) 1.27

Combination chemotherapy versus single agents followed by combination chemotherapy in stage IV non-small-cell lung cancer: a study of the Eastern Cooperative Oncology Group. J Clin Oncol (1989) 1.25

The therapy of osteogenic sarcoma: current status and thoughts for the future. J Surg Oncol (1972) 1.24

Quantitative prediction of drug toxicity in humans from toxicology in small and large animals. Cancer Res (1975) 1.22

Reduced cardiotoxicity of doxorubicin delivered on a weekly schedule. Assessment by endomyocardial biopsy. Ann Intern Med (1983) 1.19

A randomized multicenter study of remifentanil compared with halothane in neonates and infants undergoing pyloromyotomy. I. Emergence and recovery profiles. Anesth Analg (2001) 1.19

Multimodality therapy for malignant mesothelioma based on a study of natural history. Am J Med (1980) 1.19

Cardiotoxicity of epirubicin and doxorubicin: assessment by endomyocardial biopsy. Cancer Res (1986) 1.17

The dilemma of adjuvant chemotherapy for osteogenic sarcoma. Cancer Clin Trials (1980) 1.16

Management of locally advanced and disseminated breast cancer. Lancet (1981) 1.13

Surgery plus adjuvant chemotherapy--a review of therapeutic implications. I. Breast cancer. Cancer Chemother Pharmacol (1980) 1.11

A review of chemotherapy in gastric cancer. Cancer (1974) 1.09

An overview of the 1978 international meeting on comparative therapeutic trials. Biomedicine (1978) 1.08

A comparison of the quality of participation of community affiliates and that of universities in the Northern California Oncology Group. J Clin Oncol (1983) 1.07

Single and combination nonhormonal chemotherapy in breast cancer. Cancer (1972) 1.06

Adjuvant chemotherapy in lung cancer: review and prospects. Cancer (1977) 1.02

High dose methotrexate with leucovorin rescue. Rationale and spectrum of antitumor activity. Am J Med (1980) 1.02

Glutamine antagonists in chemotherapy. Adv Pharmacol Chemother (1970) 1.01

Hexamethylmelamine. An evaluation of its role in the therapy of cancer. Cancer (1976) 1.00

Calibrated phase II clinical trials in oncology. Stat Med (1987) 0.99

Prospective evaluation of cardiotoxicity during a six-hour doxorubicin infusion regimen in women with adenocarcinoma of the breast. Am J Med (1985) 0.99

Management of trials in the development of cancer chemotherapy. Br J Cancer (1978) 0.99

Integration of chemotherapy into combined modality therapy of solid tumors. IV. Malignant melanoma. Cancer Treat Rev (1974) 0.98

5-(3,3-dimethyl-l-triazeno)-imidazole-4-carboxamide (DTIC, DIC, NSC-45388)--a new antitumor agent with activity against malignant melanoma. Eur J Cancer (1972) 0.97

Nafoxidine--an antiestrogen for the treatment of breast cancer. Cancer (1976) 0.96

Effect of prolonged topotecan infusion on topoisomerase 1 levels: a phase I and pharmacodynamic study. Clin Cancer Res (1997) 0.95

Editorial: Large-bowel cancer-The current status of treatment. J Natl Cancer Inst (1976) 0.94

Patterns of failure in small cell carcinoma of the lung. Cancer (1982) 0.92

Combination chemotherapy of advanced Hodgkin's disease. A review. Cancer (1974) 0.91

Chymodiactin in patients with herniated lumbar intervertebral disc(s). An open-label, multicenter study. Spine (Phila Pa 1976) (1985) 0.90

Combined radiotherapy and chemotherapy with bleomycin and methotrexate for advanced inoperable head and neck cancer: update of a Northern California Oncology Group randomized trial. J Clin Oncol (1987) 0.89

Streptozotocin and metastatic insulinoma. Ann Intern Med (1971) 0.89

Investigational drugs under study by the United States National Cancer Institute. Cancer Treat Rev (1976) 0.88

The nitrosoureas--thoughts for the future. Cancer Treat Rep (1976) 0.88

An overview of the status of the nitrosoureas in other tumors. Cancer Chemother Rep 3 (1973) 0.87

The chemotherapy of prostatic adenocarcinoma. Ann Intern Med (1980) 0.87

Pharmacokinetics of the cardioprotector ADR-529 (ICRF-187) in escalating doses combined with fixed-dose doxorubicin. J Natl Cancer Inst (1992) 0.87

The California breast cancer law and government-mandated patient education. CA Cancer J Clin (1982) 0.86

Clinical comparison of the nitrosoureas. Cancer (1975) 0.86

Population-based study of small-cell lung cancer. J Clin Oncol (1985) 0.86

The integration of chemotherapy into combined modality treatment of solid tumors. VIII. Cervical cancer. Cancer Treat Rev (1977) 0.86

Antiestrogens in the treatment of breast cancer. Cancer Treat Rev (1976) 0.86

The integration of chemotherapy into a combined modality approached to cancer therapy. V. Squamous cell cancer of the head and neck. Cancer Treat Rev (1975) 0.86

Perspectives on research in gynecologic oncology. Cancer (1976) 0.86

Hexamethylmelamine--a new drug with activity in solid tumors. Eur J Cancer (1973) 0.85

A review of results of clinical trials with amikacin. J Infect Dis (1976) 0.85

Cancer chemotherapy: new developments and changing concepts. Drugs (1980) 0.85

Chemotherapy in advanced breast cancer. Int J Radiat Oncol Biol Phys (1978) 0.83

The chemotherapy of head and neck cancer. Semin Oncol (1977) 0.83

Chemotherapy of small-cell carcinoma of lung: a randomized comparison of alternating and sequential combination chemotherapy programs. J Clin Oncol (1984) 0.83

Preclinical rationale and phase I clinical trial of the adriamycin analog, AD 32. Recent Results Cancer Res (1981) 0.83

Gastric cancer: current status of treatment. J Natl Cancer Inst (1977) 0.83

1,3-bis(2-chloroethyl)-1-nitrosourea (bcnu) and other nitrosoureas in cancer treatment: a review. Adv Cancer Res (1972) 0.83

Methyl-CCNU inclinical cancer therapy. Cancer Treat Rev (1974) 0.83

A randomized study of doxorubicin versus doxorubicin plus cisplatin in endocrine-unresponsive metastatic prostatic carcinoma. Cancer (1985) 0.81

Maytansine: a phase I study of an ansa macrolide with antitumor activity. Cancer Treat Rep (1978) 0.81

New drugs on the horizon in bronchogenic carcinoma. Cancer (1972) 0.81

A therapeutic trial of maytansine. Cancer Clin Trials (1978) 0.81

Survival of patients with localized high-grade soft tissue sarcoma with multimodality therapy. A matched control study. Cancer (1983) 0.81

The interpretation of trials: combined hormonal therapy and chemotherapy in disseminated breast cancer. Breast Cancer Res Treat (1981) 0.81

Chromomycin A3, mithramycin, and olivomycin: antitumor antibiotics of related structure. Adv Pharmacol Chemother (1975) 0.81

Phase I trial of intravenous L-phenylalanine mustard plus the sensitizer misonidazole. Cancer Res (1983) 0.81

Monocyte activation following systemic administration of granulocyte-macrophage colony-stimulating factor. J Immunother Emphasis Tumor Immunol (1994) 0.81

Some thoughts on experimental models and their clinical correlations. Eur J Cancer (1975) 0.80

Adjuvant chemotherapy in osteogenic sarcoma: the triumph that isn't? J Clin Oncol (1984) 0.80

Current therapies in osteosarcoma. Cancer Treat Rev (1975) 0.80

Phase II study of carboplatin in recurrent ovarian cancer: severe hematologic toxicity in previously treated patients. Cancer Chemother Pharmacol (1989) 0.80

Integration of chemotherapy into combined modality treatment of solid tumors. 1. The overall strategy. Cancer Treat Rev (1974) 0.80

New chemotherapeutic agents--bleomycin and adriamycin. CA Cancer J Clin (1975) 0.80

Cancer treatment today and its impact on drug development, with special emphasis on the phase II clinical trial. J Natl Cancer Inst (1976) 0.80

Chemotherapy and genitourinary oncology. I. Bladder cancer. Cancer Treat Rev (1978) 0.80

Methodology of data reporting in advanced breast cancer trials. Cancer Chemother Pharmacol (1979) 0.79

Single-agent therapy for Hodgkin's disease. Arch Intern Med (1973) 0.79

Management of cancer pain with oral controlled-release morphine sulfate. J Clin Pharmacol (1987) 0.79

A pilot study of three sequential chemotherapeutic regimens in metastatic breast cancer. Am J Clin Oncol (1991) 0.79

Immunotherapy of cancer in man: current status and prospectus. Ann N Y Acad Sci (1976) 0.79

Serial studies of cardiac function in patients receiving adriamycin. Cancer Treat Rep (1978) 0.78

A randomized phase II trial of echinomycin, trimetrexate, and cisplatin plus etoposide in patients with metastatic nonsmall cell lung carcinoma: an Eastern Cooperative Oncology Group Study (E1587). Cancer (1998) 0.78

Sequential combination of bleomycin and mitomycin in advanced cervical cancer--an American experience: a Northern California Oncology Group study. Cancer Treat Rep (1982) 0.78

Initial clinical evaluation of N-trifluoroacetyladriamycin-14-valerate (AD-32), an adriamycin analog. Cancer Treat Rep (1979) 0.78

Cyclophosphamide in solid tumors. Cancer Treat Rev (1975) 0.78

Chemotherapy of disseminated gastric cancer. A joint effort of the Northern California Oncology Group and the Japanese Gastric Cancer Chemotherapy Group. Cancer (1983) 0.78

Tyrosine kinase inhibitors and signal transduction modulators: Rationale and current status as chemopreventive agents for prostate cancer. Urology (2001) 0.78

A randomized Phase II study of interleukin-2 with and without beta-interferon for patients with advanced non-small cell lung cancer: an Eastern Cooperative Oncology Group study (PZ586). Lung Cancer (1999) 0.78

Role of chemotherapy in the treatment of lung cancer: evolving strategies for non-small cell histologies. Int J Radiat Oncol Biol Phys (1984) 0.77